Exelixis, Inc. (EXEL) Income Statement

The sequence of year-over-year swings, from +35.6% in 2024Q2 to -10.8% in 2025Q2 and back to a steady 10% range, points to lumpy revenue that likely depends on licensing or milestone timing rather than a smooth commercial ramp. The current mid-to-high single-digit to low-double-digit cadence appears more durable than the 2024 spike, but investors should monitor whether the 2026 run-rate reflects recurring product sales or episodic recognition. Without segment disclosure in the supplied data, the driver mix remains unclear and warrants further investigation.

Gross margin stability at this level indicates limited room for expansion and little exposure to input-cost pressure, a profile typical of collaboration and royalty income rather than manufactured product sales. The 2025Q4 dip to 95.6% coincided with a COGS uptick to $26.5M, which may reflect a one-time cost item rather than a trend. Pricing power is therefore best evaluated through revenue durability rather than margin expansion.

The gap between operating margin expansion and revenue growth indicates that incremental revenue is dropping through at a high rate, consistent with a cost base that is not growing in step with sales. R&D spending has ranged from roughly $199M to $249M per quarter, so the margin trajectory depends heavily on whether R&D intensity holds. Investors should monitor whether the current overhead discipline is sustained as pipeline spending increases.